ETRADE Capital Management LLC Acquires New Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

ETRADE Capital Management LLC acquired a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,501 shares of the biopharmaceutical company’s stock, valued at approximately $210,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Commerzbank Aktiengesellschaft FI boosted its holdings in Alexion Pharmaceuticals by 151.5% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock valued at $16,145,000 after purchasing an additional 79,943 shares during the last quarter. HPM Partners LLC boosted its holdings in Alexion Pharmaceuticals by 267.2% in the second quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 4,861 shares during the last quarter. Jennison Associates LLC boosted its holdings in Alexion Pharmaceuticals by 720.0% in the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Alexion Pharmaceuticals by 4,509.0% in the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after purchasing an additional 864,967 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Alexion Pharmaceuticals by 1.2% in the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after purchasing an additional 4,115 shares during the last quarter. 94.16% of the stock is currently owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $108.90 on Wednesday. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The firm has a market cap of $24,360.00, a PE ratio of 22.28, a P/E/G ratio of 1.19 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the prior year, the firm earned $1.23 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. analysts forecast that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current year.

Several equities research analysts have commented on the stock. Leerink Swann reaffirmed a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Royal Bank Of Canada began coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 price objective (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Evercore ISI began coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 price objective for the company. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $155.06.

ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/06/etrade-capital-management-llc-acquires-new-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

What are top analysts saying about Alexion Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alexion Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit